Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573261 | 0.86 | KMT2A (0.71) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL10787479 | 0.85 | KMT2A (0.80) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL9803295 | 0.85 | KMT2A (0.80) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL30167982 | 0.85 | KMT2A (0.80) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL4509654 | 0.83 | KMT2A (0.77) | NR4A2KMT2AAKR1C3NR1H4 | |
| SCHEMBL5009881 | 0.81 | NR4A2 (0.65) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL1333545 | 0.81 | KMT2A (0.75) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL3101757 | 0.81 | NR4A2 (0.65) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL4724803 | 0.81 | NR4A2 (0.65) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL6932542 | 0.81 | KMT2A (0.75) | NR4A2KMT2AAKR1C3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105873921-B | Benzimidazole-proline derivative purposes | 爱杜西亚药品有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105793258-B | The crystalline salt form and its application of benzimidazole cycle compound | 爱杜西亚药品有限公司 | 2018-12-28 | — | — | CN | disclosed |
| US-6911442-B1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-06-28 | — | — | US | disclosed |
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | NR4A2 1681/4885KMT2A 2259/4885AKR1C3 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.